Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CG Oncology, Inc. (CGON)

CG Oncology Q1 net loss widens to $60.2 million; BLA completion guided to Q4 2026

Mixed Impact 3 of 5 earnings Written later

CG Oncology reported a first-quarter 2026 net loss of $60.2 million, or $(0.71) per share, up from $34.5 million, or $(0.45) per share, a year earlier, while total revenues rose to $1.1 million from $52 thousand. The company says it expects to complete its BLA submission for HR BCG-unresponsive NMIBC in the fourth quarter of 2026, and it ended the quarter with about $1.1 billion in cash, cash equivalents and marketable securities.

Key points

  • Net loss was $60.2 million, or $(0.71) per share, versus $34.5 million, or $(0.45) per share, in Q1 2025.
  • Total revenues were $1.1 million versus $52 thousand; R&D expenses rose to $43.7 million from $27.5 million.
  • Cash, cash equivalents and marketable securities were $1.1 billion at March 31, 2026, including about $391.4 million of net at-the-market facility proceeds in Q1.
  • BLA completion is expected in the fourth quarter of 2026, and PIVOT-006 Phase 3 topline data is anticipated in the first half of 2026.

The filing

CompanyCG Oncology, Inc. (CGON)
Form8-K, current report
Filed with the SECMay 8, 2026, 8:45 AM ET
Accession number0001193125-26-213440

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.